Related Experiment Video
Updated: Aug 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics
1Drexel University College of Medicine, 245 North 15th Street - MS 470, Room 6608 NCB, Philadelphia, PA 19102, USA. michael.d.ezekowitz@drexel.edu.
Insights
New anticoagulants are being developed to prevent stroke in patients with atrial fibrillation, offering alternatives to warfarin. These novel drugs aim to improve treatment adherence and outcomes for this growing patient population.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation and heart failure are prevalent, often coexisting conditions.
- Warfarin is effective for stroke prevention in atrial fibrillation but challenging to manage.
- Suboptimal translation of clinical trial data into practice necessitates warfarin alternatives.
Purpose of the Study:
- To review the development of novel anticoagulants as alternatives to warfarin.
- To assess the clinical progress and potential of direct thrombin inhibitors.
Main Methods:
- Review of clinical trial data for novel anticoagulants.
- Evaluation of efficacy, safety, and tolerability profiles.
Main Results:
- Ximelagatran shows anticoagulant efficacy and bleeding safety but has liver function concerns.
- Dabigatran is in earlier development with unproven clinical value.
- Warfarin's complexity limits its widespread optimal use.
Conclusions:
- Novel anticoagulants are likely to become available for stroke prevention in atrial fibrillation.
- These alternatives may increase the utilization of anticoagulation therapy.
- Further research is needed to resolve safety concerns, such as ximelagatran's liver effects.
Abstract:
Atrial fibrillation and heart failure are growing epidemics in the developed world and often coexist. From clinical trials, warfarin is highly effective in reducing stroke in patients with atrial fibrillation. Equally important is the fact that in spite of well-designed trials, translation of the results of the data from the trials into clinical practice has been less than optimal. One of the reasons is that warfarin is a difficult drug to use. Thus there has been a concerted effort to develop an alternative to warfarin. Ximelagatran and Dabigatran, both direct thrombin inhibitors, are the furthest along in clinical development. Ximelagatran, while highly effective as an anticoagulant and safe with regard to bleeding, has been associated with liver function abnormalities; the importance of which needs resolution. Dabigatran is much earlier in development and is currently of unproven value. It is highly likely that alternatives to warfarin for stroke prevention will be available in the future and will likely result in a higher utilization rate of anticoagulants in patients with atrial fibrillation.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

